Viking Global Investors
CLDX icon

Viking Global Investors’s Celldex Therapeutics CLDX Stock Holding History

Viking Global Investors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,337,854
Closed -$63M – 94
2022
Q2 		$63M Buy
2,337,854
+491,207
+27% +$14.3M 0.29% 62
2022
Q1 		$62.9M Buy
1,846,647
+1,088,766
+144% +$34.8M 0.25% 71
2021
Q4 		$29.3M Sell
757,881
-4,415
-0.6% -$192K 0.08% 100
2021
Q3 		$41.2M Buy
+762,296
New +$35.8M 0.11% 87
2013
Q4 		– Sell
-44,834
Closed -$23.8M – 68
2013
Q3 		$23.8M Buy
+44,834
New +$15.4M 0.13% 55

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Viking Global Investors's CLDX Position: Q3 2022 in Review

Viking Global Investors sold out of Celldex Therapeutics (CLDX) in Q3 2022, closing a stake of 2,337,854 shares — an estimated $63M sold.

Viking Global Investors first reported a position in CLDX in Q3 2013 and held it in 5 quarters. The position peaked at $63M in Q2 2022. 159 funds tracked by Wall St. Rank hold CLDX as of Q3 2022.

  • Viking Global Investors reported no remaining Celldex Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Viking Global Investors sold 2,337,854 Celldex Therapeutics shares in Q3 2022, an estimated $63M.
  • Viking Global Investors first reported a position in Celldex Therapeutics in Q3 2013 and held it in 5 quarters.
  • Viking Global Investors's Celldex Therapeutics position peaked at $63M in Q2 2022.
  • 159 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2022.

Based on Viking Global Investors's 13F filing for Q3 2022, filed 14 Nov 2022.